Advanced in WT1-Related Wilms Tumor Syndromes

Dr. George K. Philips

Hematology Oncology | Oncology | Hematology
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
Accepting New Patients
Offers Telehealth
Advanced in WT1-Related Wilms Tumor Syndromes
Mgmc LLC
3800 Reservoir Rd Nw, 
Washington, DC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

George Philips is a Hematologist Oncology specialist and an Oncologist in Washington, Washington, D.c.. Dr. Philips is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer. Dr. Philips is currently accepting new patients.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in VT
Hospital Affiliations
Medstar Georgetown University Hospital
Medstar Washington Hospital Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MGMC LLC
3800 Reservoir Rd Nw, Washington, DC 20007

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
A Randomized Phase 2 Trial of 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With High-Risk Castrate Biochemically Relapsed Prostate Cancer After Local Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2025
Intervention Type: Drug
Study Drugs: 177Lu-J591, Ketoconazole, Hydrocortisone, 111In-J591
Study Phase: Phase 2
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Phase II Trial of Gemcitabine-Eribulin (GE) in Cisplatin Ineligible Patients With Advanced or Unresectable Urothelial Carcinoma of the Bladder
Enrollment Status: Completed
Publish Date: December 16, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

17 Total Publications

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial.
Journal: The oncologist
Published: July 01, 2022
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Jeanny B. Aragon-Ching
Oncology | Hematology | Hematology Oncology

Inova Health Care Services

3300 Gallows Rd, 
Falls Church, VA 
 (9.1 miles away)
Languages Spoken:
English, Filipino
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeanny Aragon-Ching is an Oncologist and a Hematologist in Falls Church, Virginia. Dr. Aragon-Ching is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Urothelial Cancer, Bladder Cancer, Orchiectomy, and Prostatectomy. Dr. Aragon-Ching is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nancy A. Dawson
Oncology | Hematology Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Nancy A. Dawson
Oncology | Hematology Oncology | Hematology

Medstar Medical Group Ii LLC

3800 Reservoir Rd Nw, 
Washington, DC 
 (0.1 miles away)
202-444-2000
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nancy Dawson is an Oncologist and a Hematologist Oncology provider in Washington, Washington, D.c.. Dr. Dawson has been practicing medicine for over 46 years and is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Prostate Cancer, Familial Prostate Cancer, WT1-Related Wilms Tumor Syndromes, and Chromophobe Renal Cell Carcinoma. Dr. Dawson is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Noah M. Hahn
Hematology Oncology | Oncology | Hematology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Noah M. Hahn
Hematology Oncology | Oncology | Hematology

Johns Hopkins University

600 N Wolf St, 
Baltimore, MD 
 (37.2 miles away)
410-955-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Noah Hahn is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy. Dr. Hahn is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Philips's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 28 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile